info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Cardiomyopathy Medication Companies

Cardiomyopathy refers to diseases of the heart muscle, where the heart becomes enlarged, thickened, or rigid, leading to decreased heart function. Cardiomyopathy medication companies specialize in the research, development, manufacturing, and distribution of pharmaceuticals designed to manage and treat cardiomyopathy. The medications developed by these companies aim to address symptoms, slow the progression of the disease, and improve the quality of life for individuals with cardiomyopathy. 

Cardiomyopathy Medication Key Companies

 

Latest Cardiomyopathy Medication Companies Update


Cytokinetics (US) Received FDA approval for aficamten (Myodist®), the first FDA-approved medication specifically for hypertrophic cardiomyopathy (HCM).Partnering with healthcare providers to educate clinicians and improve access to aficamten for patients with HCM.


Bristol Myers Squibb (US) Acquired Karuna Therapeutics and RayzeBio to strengthen their neuroscience and oncology portfolios, offering potential benefits for future cardiomyopathy-related drug development.Continued marketing Camzyos (Mavacamten), their FDA-approved medication for symptomatic HCM, focusing on expanding patient access and exploring its use in early-stage disease.


Novartis (Switzerland) Received breakthrough therapy designation for omecamtiv mecarbil (OMT) from the FDA for the treatment of heart failure with preserved ejection fraction (HFpEF).Conducting Phase III clinical trials for OMT, aiming to establish its efficacy and safety as a potential novel treatment option for HFpEF.


Tenaya Therapeutics (US) Initiated Phase IIb clinical trials for levosimendin, a potential treatment for HCM and HFpEF, to evaluate its effectiveness in improving cardiac function and symptoms.Collaborating with research institutions to investigate the underlying mechanisms of cardiomyopathy and identify new therapeutic targets.


American Heart Association (AHA) Updated their guidelines for the management of heart failure, emphasizing personalized treatment plans and including recommendations on novel medication options for specific cardiomyopathy types.Providing educational resources and patient support programs to raise awareness about cardiomyopathy and empower individuals to manage their condition effectively.


List of Cardiomyopathy Medication Key Companies in The Market



  • Pfizer Inc.

  • PhaseBio Pharmaceuticals, Inc.

  • Array Biopharma, Inc.

  • AstraZeneca

  • Sanofi-Aventis US LLC

  • Hoffmann-La Roche Ltd

  • Merck & Co., Inc.

  • Capricor Therapeutics

  • MyoKardia

  • Janssen Products, LP

  • Ionis Pharmaceuticals, Inc.

  • Medtronic

  • Becton And Dickson & Co.

  • Biomerieux

  • Teva Pharmaceutical Industries Ltd


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.